Orthocell Hits 100 Unit Sales Milestone in $1.6B US Nerve Repair Market
Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.
- 100 units of Remplir™ sold in the US nerve repair market
- 17 hospital Value Analysis Committee approvals secured out of 61 submissions
- Distributor network spans 25 states covering 40% of US population
- Over 250 surgeons engaged through medical education programs
- Plans to expand US adoption and initiate Canadian surgeries in 2026
Orthocell Hits Early US Adoption Milestone
Orthocell Limited (ASX, OCC), a regenerative medicine company focused on nerve repair, has announced it has sold 100 units of its flagship product Remplir™ in the United States. This milestone marks an important early step in penetrating the US$1.6 billion nerve repair market, underscoring growing clinical acceptance of the product in complex peripheral nerve surgeries.
The achievement reflects the success of Orthocell’s targeted commercial strategy, which combines a robust medical education campaign with a specialist distributor network. Currently, the company’s distribution partners cover 25 states, reaching approximately 40% of the US population. This broad footprint is critical for building surgeon familiarity and facilitating procedural uptake.
Hospital Approvals Pave the Way for Growth
Orthocell’s progress is further evidenced by its active engagement with hospital Value Analysis Committees (VACs), which act as gatekeepers for product adoption within hospital systems. The company has submitted 61 applications and secured 17 approvals ahead of schedule, a positive indicator for future market access. These approvals are essential for scaling sales and embedding Remplir™ into surgical practice.
Supporting this momentum, Orthocell has engaged over 250 surgeons through its medical education programs and maintains contracts with 14 Medical Advisory Board members. This surgeon engagement is vital for driving early case volumes and fostering long-term adoption.
Looking Ahead, Expansion and International Growth
Orthocell’s CEO, Paul Anderson, highlighted that the early US uptake is exceeding expectations and mirrors the positive trajectory seen in Australia. With a strong balance sheet of approximately A$50 million in cash and no debt, the company is well-positioned to continue investing in clinical evidence and education initiatives to support growth.
Looking forward, Orthocell plans to accelerate US adoption throughout 2026 and leverage its US experience to launch Remplir™ surgeries in Canada early next year. The company targets a total addressable market exceeding US$3.5 billion across selected jurisdictions, signaling substantial growth potential if current trends continue.
Orthocell’s strategic approach, combining clinical validation, surgeon engagement, and hospital approvals, sets a solid foundation for scaling its nerve repair technology in North America and beyond.
Bottom Line?
Orthocell’s early US sales milestone signals promising momentum, but sustained growth hinges on expanding hospital approvals and surgeon adoption.
Questions in the middle?
- How quickly will Orthocell secure additional hospital VAC approvals to broaden US market access?
- What impact will the Canadian launch have on overall sales and international expansion?
- How will ongoing clinical evidence and surgeon feedback influence Remplir™’s adoption curve?
